AstraZeneca’s CALQUENCE demonstrates enhanced efficacy in mantle cell lymphoma trial
AstraZeneca has announced significant outcomes from the ECHO Phase III trial, highlighting the effectiveness of its drug CALQUENCE (acalabrutinib) when combined with bendamustine and rituximab in treating previously untreated patients with mantle cell lymphoma (MCL). Presented at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain, the findings reveal a statistically significant and […]